• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病患者艰难梭菌感染:一项病例对照研究。

Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.

作者信息

Vitikainen Krista, Haapamäki Johanna, Färkkilä Martti, Anttila Veli-Jukka, Arkkila Perttu

机构信息

a Department of Gastroenterology , Helsinki University Central Hospital , Helsinki , Finland.

b Department of Infectious Diseases , Helsinki University Central Hospital , Helsinki , Finland.

出版信息

Scand J Gastroenterol. 2018 Aug;53(8):947-951. doi: 10.1080/00365521.2018.1492012. Epub 2018 Jul 25.

DOI:10.1080/00365521.2018.1492012
PMID:30041549
Abstract

OBJECTIVE

Characterization of predisposing factors for Clostridium difficile infection recurrence (rCDI) and outcome in inflammatory bowel disease (IBD) patients.

METHODS

Clinical characteristics of 167 inflammatory bowel disease patients with Clostridium difficile infection (IBD-CDI cohort) treated in Helsinki University Central Hospital were gathered. Medical history of the last three months preceding a toxin positive CDI test was recorded. Parameters, including ribotype of C. difficile, mortality and recurrence were compared with age and gender-matched C. difficile patients (CDI cohort).

RESULTS

No difference was found in rCDI between IBD-CDI and CDI cohorts. As compared with IBD subtypes, rCDI was least common among patients with Crohn's disease. The use of immunosuppressant therapy was higher in IBD patients with two or more CDI episodes. C. difficile ribotype 027 increased the rates for rCDI in IBD patients but not in non-IBD-CDI patients. The prevalence of 027 ribotype and mortality rates did not differ significantly among the cohorts. None of the IBD patients underwent colectomy upon CDI.

CONCLUSION

IBD patients are not more susceptible for rCDI than non-IBD patients. Predisposing factors for rCDI among IBD patients are associated with immunosuppressant treatments, colon affecting IBD and CDI caused by ribotype 027. CDI does not worsen the prognosis of IBD patients.

摘要

目的

确定艰难梭菌感染复发(rCDI)的诱发因素以及炎症性肠病(IBD)患者的预后情况。

方法

收集了在赫尔辛基大学中心医院接受治疗的167例患有艰难梭菌感染的炎症性肠病患者(IBD-CDI队列)的临床特征。记录毒素阳性CDI检测前三个月的病史。将包括艰难梭菌核糖型、死亡率和复发率等参数与年龄和性别匹配的艰难梭菌感染患者(CDI队列)进行比较。

结果

IBD-CDI队列和CDI队列在rCDI方面未发现差异。与IBD亚型相比,rCDI在克罗恩病患者中最不常见。在有两次或更多次CDI发作的IBD患者中,免疫抑制剂治疗的使用率更高。艰难梭菌核糖型027增加了IBD患者的rCDI发生率,但在非IBD-CDI患者中未增加。各队列中027核糖型的患病率和死亡率无显著差异。没有IBD患者因CDI接受结肠切除术。

结论

IBD患者并不比非IBD患者更容易发生rCDI。IBD患者中rCDI的诱发因素与免疫抑制剂治疗、影响结肠的IBD以及由核糖型027引起的CDI有关。CDI不会使IBD患者的预后恶化。

相似文献

1
Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.炎症性肠病患者艰难梭菌感染:一项病例对照研究。
Scand J Gastroenterol. 2018 Aug;53(8):947-951. doi: 10.1080/00365521.2018.1492012. Epub 2018 Jul 25.
2
Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.炎症性肠病患者艰难梭菌感染的复发:累犯研究
Am J Gastroenterol. 2016 Aug;111(8):1141-6. doi: 10.1038/ajg.2016.187. Epub 2016 May 24.
3
Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus.艰难梭菌感染与不良结局的炎症性肠病患者的病例对照研究,以及艰难梭菌与巨细胞病毒合并感染患者的研究。
Dig Dis Sci. 2018 Nov;63(11):3074-3083. doi: 10.1007/s10620-018-5230-1. Epub 2018 Aug 9.
4
Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.炎症性肠病影响复发性艰难梭菌感染粪便微生物群移植的结果。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8. doi: 10.1016/j.cgh.2016.02.018. Epub 2016 Feb 22.
5
Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.炎症性肠病合并艰难梭菌感染患者中,使用皮质类固醇与免疫调节剂或生物制剂进行结肠手术的风险
Inflamm Bowel Dis. 2019 Feb 21;25(3):610-619. doi: 10.1093/ibd/izy291.
6
Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.炎症性肠病患者对艰难梭菌感染的宿主免疫反应
Inflamm Bowel Dis. 2016 Apr;22(4):853-61. doi: 10.1097/MIB.0000000000000696.
7
Clostridium difficile isolated from faecal samples in patients with ulcerative colitis.从溃疡性结肠炎患者粪便样本中分离出艰难梭菌。
BMC Infect Dis. 2019 Apr 30;19(1):361. doi: 10.1186/s12879-019-3965-8.
8
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.免疫抑制治疗加重与艰难梭菌感染后不良结局无关。
Inflamm Bowel Dis. 2019 Mar 14;25(4):775-781. doi: 10.1093/ibd/izy308.
9
Incidence and risk factors of Clostridium difficile infection in patients with inflammatory bowel disease.炎症性肠病患者艰难梭菌感染的发病率及危险因素
Rev Med Chir Soc Med Nat Iasi. 2015 Jan-Mar;119(1):81-6.
10
Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease.波兰儿科门诊炎症性肠病患者艰难梭菌感染。
Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1265-70. doi: 10.1007/s10096-010-0997-9. Epub 2010 Jun 26.

引用本文的文献

1
Higher disease activity of inflammatory bowel disease predisposes to infection.炎症性肠病较高的疾病活动度易引发感染。
Therap Adv Gastroenterol. 2025 Feb 17;18:17562848251318292. doi: 10.1177/17562848251318292. eCollection 2025.
2
Is Increased BMI a Risk Factor for Developing Severe Clostridioides Difficile Infection? A Retrospective Study.体重指数增加是发生严重艰难梭菌感染的危险因素吗?一项回顾性研究。
J Community Hosp Intern Med Perspect. 2022 Nov 7;12(6):43-50. doi: 10.55729/2000-9666.1123. eCollection 2022.
3
Application of Procalcitonin for the Rapid Diagnosis of Infection in Patients with Inflammatory Bowel Disease.
降钙素原在炎症性肠病患者感染快速诊断中的应用
Diagnostics (Basel). 2022 Dec 9;12(12):3108. doi: 10.3390/diagnostics12123108.
4
Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis.儿童和青少年炎症性肠病患者艰难梭菌感染的危险因素:系统评价和荟萃分析。
World J Pediatr. 2022 Jan;18(1):27-36. doi: 10.1007/s12519-021-00486-1. Epub 2021 Nov 20.
5
Novel risk factors and outcomes in inflammatory bowel disease patients with infection.炎症性肠病合并感染患者的新型危险因素及结局
Therap Adv Gastroenterol. 2021 Mar 12;14:1756284821997792. doi: 10.1177/1756284821997792. eCollection 2021.
6
MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.艰难梭菌感染和炎症性肠病的微生物组学见解。
Gut Microbes. 2020 Nov 9;12(1):1725220. doi: 10.1080/19490976.2020.1725220. Epub 2020 Mar 4.